The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

With school back in session, Purdue University saw a record number of applicants. Wall Street analyst Jane King says Purdue ...

The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly's new treatment for moderate to severe eczema ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...

The drug is administered via injection and offers long-lasting efficacy, with a monthly maintenance dose required after the ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

The FDA has approved Lilly’s Ebglyss (lebrikizumab-lbkz) for the treatment of moderate to severe atopic dermatitis in adults ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

INDIANAPOLIS–The U.S. Food and Drug Administration has approved Eli Lilly’s new treatment for moderate to severe eczema. It’s ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for ...

According to a study, Lilly says 38% of people who took the injection achieved clear or "almost-clear" skin at 16 weeks.